91 related articles for article (PubMed ID: 6985358)
1. An examination of tumor antigen loss in spontaneous metastases.
Dennis JW; Donaghue TP; Kerbel RS
Invasion Metastasis; 1981; 1(2):111-25. PubMed ID: 6985358
[TBL] [Abstract][Full Text] [Related]
2. Partial reversion of the metastatic phenotype in a wheat germ agglutinin-resistant mutant of the murine tumor cell line MDAY-D2 selected with Bandeiraea simplicifolia seed lectin.
Dennis JW
J Natl Cancer Inst; 1985 May; 74(5):1111-20. PubMed ID: 3858579
[TBL] [Abstract][Full Text] [Related]
3. Carcinogenicity of tumor cell populations: origin of a putative H-2 isoantigenic loss variant tumor.
Kerbel RS; Florian M; Man MS; Dennis J; McKenzie IF
J Natl Cancer Inst; 1980 May; 64(5):1221-30. PubMed ID: 6929020
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines.
Dennis JW; Laferté S; Man MS; Elliott BE; Kerbel RS
Int J Cancer; 1984 Nov; 34(5):709-16. PubMed ID: 6437992
[TBL] [Abstract][Full Text] [Related]
5. Membrane-associated alterations detected in poorly tumorigenic lectin-resistant variant sublines of a highly malignant and metastatic murine tumor.
Dennis JW; Donaghue TP; Kerbel RS
J Natl Cancer Inst; 1981 Jan; 66(1):129-39. PubMed ID: 6935454
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor.
Kerbel RS; Lagarde AE; Dennis JW; Donaghue TP
Mol Cell Biol; 1983 Apr; 3(4):523-38. PubMed ID: 6687920
[TBL] [Abstract][Full Text] [Related]
7. Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage- and natural killer cell-resistant tumor variants.
Nestel FP; Casson PR; Wiltrout RH; Kerbel RS
J Natl Cancer Inst; 1984 Aug; 73(2):483-91. PubMed ID: 6589440
[TBL] [Abstract][Full Text] [Related]
8. A fluctuation analysis of the rate of reexpression of the metastatic potential in a nonmetastatic mutant of the MDAY-D2 murine tumor.
Lagarde AE
Invasion Metastasis; 1983; 3(1):52-64. PubMed ID: 6677620
[TBL] [Abstract][Full Text] [Related]
9. Genotypic and phenotypic evolution of a murine tumor during its progression in vivo toward metastasis.
Lagarde AE; Donaghue TP; Dennis JW; Kerbel RS
J Natl Cancer Inst; 1983 Jul; 71(1):183-91. PubMed ID: 6575202
[TBL] [Abstract][Full Text] [Related]
10. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens.
Fuji H; Iribe H
Cancer Res; 1986 Nov; 46(11):5541-7. PubMed ID: 3489524
[TBL] [Abstract][Full Text] [Related]
11. Different class I antigen oligosaccharides on a murine tumor and a lectin-resistant variant are not responsible for the differential recognition of the tumors by CTL.
Degen E; Laferté S; Elliott BE; Williams DB
Int J Cancer; 1989 May; 43(5):828-36. PubMed ID: 2497074
[TBL] [Abstract][Full Text] [Related]
12. Immunologic studies of membrane mutants of a highly metastatic murine tumor.
Kerbel RS
Am J Pathol; 1979 Dec; 97(3):609-22. PubMed ID: 507193
[TBL] [Abstract][Full Text] [Related]
13. Persistence of immunogenic pulmonary metastases in the presence of protective anti-melanoma immunity.
Donawho CK; Pride MW; Kripke ML
Cancer Res; 2001 Jan; 61(1):215-21. PubMed ID: 11196164
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
16. Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells.
Kündig TM; Bachmann MF; Lefrancois L; Puddington L; Hengartner H; Zinkernagel RM
J Immunol; 1993 May; 150(10):4450-6. PubMed ID: 8097755
[TBL] [Abstract][Full Text] [Related]
17. Tumour cell variants with increased immunogenicity obtained by mutagen treatment.
Boon T; Maryanski J
Cancer Surv; 1985; 4(1):135-48. PubMed ID: 3879855
[TBL] [Abstract][Full Text] [Related]
18. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
19. Glycosphingolipids of lectin-resistant mutants of the highly metastatic mouse tumor cell line, MDAY-D2.
Laferté S; Fukuda MN; Fukuda M; Dell A; Dennis JW
Cancer Res; 1987 Jan; 47(1):150-9. PubMed ID: 3791202
[TBL] [Abstract][Full Text] [Related]
20. Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.
Lewis JD; Shearer MH; Kennedy RC; Bright RK
Cancer Res; 2005 Apr; 65(7):2938-46. PubMed ID: 15805297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
